Pharmabiz14h
US FDA grants breakthrough therapy designation to GSK’s B7-H3-targeted ADC, GSK’227 to treat relapsed or refractory osteosarcoma
US FDA grants breakthrough therapy designation to GSK’s B7-H3-targeted ADC, GSK’227 to treat relapsed or refractory osteosarcoma: London, UK Wednesday, January 8, 2025, 10:00 ...
Pharmabiz16h
Govt yet to notify rules for compounding offences as per amendments introduced through Jan Vishwas Act
Govt yet to notify rules for compounding offences as per amendments introduced through Jan Vishwas Act: Shardul Nautiyal, Mumbai Wednesday, January 8, 2025, 08:00 Hrs [IST] Despit ...
Pharmabiz16h
Govt must adopt a pragmatic approach on revised Schedule M similar to US FDA compliance: Manoj Palrecha
Govt must adopt a pragmatic approach on revised Schedule M similar to US FDA compliance: Manoj Palrecha: Nandita Vijayasimha, Bengaluru Wednesday, January 8, 2025, 08:00 Hrs [IST] ...
Pharmabiz16h
TN DCA gearing up for inspection of pharma units to ensure compliance with revised Schedule M
Peethaambaran Kunnathoor, Chennai Wednesday, January 8, 2025, 08:00 Hrs [IST] ...
Pharmabiz13h
US FDA issues comprehensive draft guidance for developers of AI -enabled medical devices
US FDA issues comprehensive draft guidance for developers of AI -enabled medical devices: Maryland Wednesday, January 8, 2025, 11:00 Hrs [IST] The US Food and Drug Administration ...
Pharmabiz15h
MTaI to host MedTekon 2025 in New Delhi on January 30
Our Bureau, New Delhi Wednesday, January 8, 2025, 09:00 Hrs [IST] Medical Technology Association of India (MTaI), which repr ...
Pharmabiz16h
Indian health sector navigating complexities of M&As: Harsh Vaish
Harsh Vaish: Nandita Vijayasimha, Bengaluru Wednesday, January 8, 2025, 08:00 Hrs [IST] Mergers and Acquisitions (M&As) have ...
Pharmabiz16h
MAKE HOSPITALS A SAFER PLACE
Of course, safety and security in hospitals have been a matter of great concern in the country. There have been reports of intermittent violence against the medical fraternity by the relatives of the ...
Pharmabiz6h
Adcentrx begins patient dosing in phase 1a/b study of ADRX-0405, a potential first-in-class ADC targeting STEAP1 to treat advanced solid tumours
Adcentrx begins patient dosing in phase 1a/b study of ADRX-0405, a potential first-in-class ADC targeting STEAP1 to treat advanced solid tumours: San Diego, California Wednesday, ...
Pharmabiz7h
Norgine submits MAA to EMA for eflornithine in high-risk neuroblastoma
Norgine submits MAA to EMA for eflornithine in high-risk neuroblastoma: Netherlands Wednesday, January 8, 2025, 17:00 Hrs [IST] Norgine, a uniquely positioned, specialty pharmaceu ...
Pharmabiz11h
Rajya Sabha MP seeks health ministry to use powers to support local manufacturing of SMA drug risdiplam
Our Bureau, New Delhi Wednesday, January 8, 2025, 13:50 Hrs [IST] ...
Pharmabiz11h
Arcturus Therapeutics initiates patient dosing in phase 2 multiple ascending dose studies for CF and OTC deficiency
Arcturus Therapeutics initiates patient dosing in phase 2 multiple ascending dose studies for CF and OTC deficiency: San Diego Wednesday, January 8, 2025, 13:00 Hrs [IST] Arcturus ...